作者：Ammer E, Nietzsche S, Rien C, Kühnl A, Mader T, Heller R, Sauerbrei A, Henke A.
【摘自】醫(yī)學(xué)微生物免疫學(xué)雜志， 2015年第204卷6期。
【文獻(xiàn)摘要】
抑制代謝途徑的藥物不僅可以減少人類糖尿病誘導(dǎo)的疾病風(fēng)險,同時也可能阻礙病毒病原體的復(fù)制。為了研究美國食品和藥物管理局批準(zhǔn)的抗肥胖藥物奧利司他對不同人類致病病毒的抗病毒活性,作者進(jìn)行了幾個抗病毒研究、電鏡分析以及脂肪酸吸收實驗。結(jié)果表明，非細(xì)胞毒性濃度的奧利司他減少了柯薩奇病毒B3(CVB3)在不同的細(xì)胞類型的復(fù)制。此外,奧利司他還顯示出了細(xì)胞保護(hù)作用，并可以改變存在于柯薩奇B3病毒感染細(xì)胞中的病毒復(fù)制所必須的多層結(jié)構(gòu)的形成。奧利司他能通過對根皮素的管理降低從細(xì)胞外環(huán)境中吸收脂肪酸，從而在一定程度上影響柯薩奇B3病毒的復(fù)制；最后，奧利司他可顯著降低水痘-帶狀皰疹病毒的復(fù)制。
【文獻(xiàn)原文】
The anti-obesity drug orlistat reveals anti-viral activity.
Author: Ammer E1, Nietzsche S2, Rien C1, Kühnl A1, Mader T1, Heller R3, Sauerbrei A1, Henke A4.
Author information：
1Institute of Virology and Antiviral Therapy, Jena University Hospital, Friedrich Schiller University Jena, Hans-Kn?ll-Str. 2, 07745, Jena, Germany.
2Center of Electron Microscopy, Jena University Hospital, Friedrich Schiller University Jena, Jena, Germany.
3Institute for Molecular Cell Biology, Center for Molecular Biomedicine, Jena University Hospital, Friedrich Schiller University Jena, Jena, Germany.
4Institute of Virology and Antiviral Therapy, Jena University Hospital, Friedrich Schiller University Jena, Hans-Kn?ll-Str. 2, 07745, Jena, Germany.
Quote From: Med Microbiol Immunol. 2015 Dec;204(6):635-45.
【ABSTRACT】
The administration of drugs to inhibit metabolic pathways not only reduces the risk of obesity-induced diseases in humans but may also hamper the replication of different viral pathogens. In order to investigate the value of the US Food and Drug Administration-approved anti-obesity drug orlistat in view of its anti-viral activity against different human-pathogenic viruses, several anti-viral studies, electron microscopy analyses as well as fatty acid uptake experiments were performed. The results indicate that administrations of non-cytotoxic concentrations of orlistat reduced the replication of coxsackievirus B3 (CVB3) in different cell types significantly. Moreover, orlistat revealed cell protective effects and modified the formation of multi-layered structures in CVB3-infected cells, which are necessary for viral replication. Lowering fatty acid uptake from the extracellular environment by phloretin administrations had only marginal impact on CVB3 replication. Finally, orlistat reduced also the replication of varicella-zoster virus moderately but had no significant influence on the replication of influenza A viruses. The data support further experiments into the value of orlistat as an inhibitor of the fatty acid synthase to develop new anti-viral compounds, which are based on the modulation of cellular metabolic pathways.
文獻(xiàn)詳情：http://www.ncbi.nlm.nih.gov/pubmed/?term=The+anti-obesity+drug+orlistat+reveals+anti-viral+activity